Form 4: Eli Lilly Executive Exercises RSUs, Sells Shares for Tax

Eli Lilly's EVP & President, International, Patrik Jonsson, acquired shares through RSU vesting and subsequently sold a portion for tax obligations.

Summary

• Patrik Jonsson, EVP & President, LLY International, reported changes in his beneficial ownership of Eli Lilly & Co (LLY) common stock.
• On February 1, 2026, Jonsson acquired 3,930 shares of common stock through the vesting of Restricted Stock Units (RSUs) at a price of $0.
• Concurrently, on February 1, 2026, Jonsson disposed of 1,752.071 shares of common stock at a price of $1,037.15 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Jonsson directly owns 55,828.568 shares of common stock and indirectly owns 608.95 shares in a 401(k) plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's a disposition of shares, it's for tax purposes following an RSU vesting, indicating executive compensation and continued equity holding, which is generally a positive sign of alignment.

Positives

• The acquisition of 3,930 shares through RSU vesting indicates the executive's continued equity participation and alignment with shareholder interests.
• The vesting of Restricted Stock Units at a $0 cost represents a compensation benefit to the executive.

Negatives

• The disposition of 1,752.071 shares, while for tax purposes, reduces the executive's direct beneficial ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, such as RSU vestings and subsequent tax-related sales, are routine events in publicly traded companies, especially for executives whose compensation packages often include equity awards. These transactions reflect standard compensation practices within the pharmaceutical industry, where attracting and retaining top talent often involves significant equity incentives.

Comparison to Industry Standards

• The vesting of Restricted Stock Units (RSUs) is a common form of executive compensation across industries, including pharmaceuticals, aligning executive interests with long-term shareholder value.
• The 'sell-to-cover' transaction for tax obligations is a standard practice when equity awards vest, observed in companies comparable to Eli Lilly, such as Pfizer (PFE) or Johnson & Johnson (JNJ), where executives frequently sell a portion of vested shares to satisfy statutory tax withholdings without needing to use personal funds.

Stakeholder Impact

• Shareholders: The executive's continued significant direct and indirect ownership aligns their interests with shareholders, though the tax-related sale slightly reduces direct holdings.
• Employees: This filing pertains to executive compensation, which can influence broader compensation strategies and morale within the company.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax-related sale). It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and do not signal a significant shift in the executive's confidence or the company's outlook.

Keywords

Eli Lilly, LLY, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Sale, Tax Withholding